{"filings":[{"id":442880,"accession_number":"0001778922-26-000033","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-05-14T20:15:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"SpyGlass Pharma reports Q1 loss of $13.8M; Phase 1/2 BIM-IOL data shows 98% drop-free, 34% IOP reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.8M ($0.69/share) vs $8.8M loss in Q1 2025; R&D expenses $8.5M, G&A $6.9M.","Cash & investments $251M as of Mar 31, 2026, funded through 2028 after $172.5M IPO in Feb 2026.","Phase 1/2 BIM-IOL 12-mo data: 98% drop-free, 34% mean IOP reduction from baseline at 78-mcg dose.","Phase 3 registrational trials SGP-005 and SGP-006 continue; enrollment completion expected in 2027.","Bimatoprost Drug Ring (BIM-DRS) first-in-human trial on track to start H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108400,"accession_number":"0001778922-26-000018","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SpyGlass Pharma reports FY2025 net loss $39.9M; positive Phase 1/2 data and $172.5M IPO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.6M in Q4 2025 ($5.72/sh) and $39.9M for FY2025 ($17.98/sh).","Cash $107.4M at Dec 2025; plus $172.5M IPO gross proceeds; runway through 2028.","Positive 12-month Phase 1/2 data: 97% of patients off IOP-lowering drops; mean IOP reduction 34-42%.","Phase 3 trials (SGP-005/SGP-006) enrolling; full enrollment expected 2027; BIM-DRS FIH trial in H2 2026.","Appointed Jean-Frédéric Viret as CFO and Habib Dable to board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108399,"accession_number":"0001778922-26-000004","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SpyGlass Pharma reports positive 12-month Phase 1/2 results for BIM-IOL System; 97% off topical drops","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["97% of patients on BIM-IOL System were free from all topical IOP-lowering medications at 12 months.","Mean IOP reduction from baseline: 34% (78-mcg) and 42% (39-mcg) vs 35% for timolol control.","100% of BIM-IOL patients achieved BCDVA of 20/32 or better; mean BCDVA equivalent to 20/20.","Adverse event rates similar across groups (36.7%-43.5%); no serious ocular AEs observed.","Company is enrolling two identical registrational Phase 3 trials of the 78-mcg dose (initiated Jan 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108398,"accession_number":"0001628280-26-008073","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SpyGlass Pharma discloses FY2025 performance cash bonuses for named executive officers","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation Committee approved FY2025 bonuses on Feb 12, 2026.","CEO Patrick Mooney: $215,088 bonus; total compensation $3,322,711.","President/CMO Malik Y. Kahook: $125,975 bonus; total $2,484,469.","Chief R&D Officer Chetan Pujara: $126,289 bonus; total $1,539,952.","Bonuses previously undisclosed in S-1; updated comp table filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108397,"accession_number":"0001628280-26-006460","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"SpyGlass Pharma closes IPO, raises $172.5M at $16.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed IPO of 10,781,250 shares (incl. full exercise of underwriters' option for 1.4M additional shares) at $16.00/share.","Aggregate gross proceeds of $172.5 million before underwriting discounts and offering expenses.","Common stock began trading on Nasdaq Global Select Market under ticker SGP on February 6, 2026.","Habib Dable appointed to board as Class I director and to compensation committee; receives standard director compensation and option grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}